Annual Report to shareholders
Released
Released
Announcement PDF
Annual Report
2020
myriad data.
individual care.
We use novel interventions, build new
technologies and develop decision
support tools to elevate care and
deliver valuable insights for unmet
medical needs.
Contents
Emyria Ltd Annual Report
Letter from the Chairman
4
Meet the team
6–7
Company snapshot
8–9
Review of operations
10 – 11
Emerald Clinics
12 – 13
Openly
14 – 15
Directors’ Report
16 - 35
Financial Report
36 - 75
Audit Opinion
76 - 81
Corporate Governance Statement
82 - 93
Additional ASX Information
94 - 97
Corporate Directory
98
From the Chairman
We started the year as Emerald Clinics Limited, successfully listed on the ASX and have ticked off a number of
milestones in just six months – with some of our most significant projects launched in response to a drastically
changing world and healthcare system, in the age of COVID-19.
Our innovative business model is allowing us to respond to these emerging challenges as opportunities,
and to set the pace for this work, I am proud to say we are starting the new fiscal year with a new name
and fresh identity.
Welcome to Emyria Limited (Emyria).
Our ticker code (ASX:EMD) remains unchanged, but our new brand will focus on positioning and growing our
company on the world stage – beyond our network of physical clinics and the vital treatments we offer – to a
leadership role in digitally-connected and patient-centric healthcare. Care that also generates high quality
clinical evidence where it matters most, in the real world.
Emyria is emerging as a leader in the generation of real-world evidence (RWE) – which works squarely at the
intersection of understanding and improving the whole patient experience and clinical outcomes (for patients),
whilst meeting the need for quality clinical evidence to progress the development of superior and novel
treatments (for researchers, clinicians, and regulators). Emyria’s world-class technology systems are a powerful
vehicle through which we can capture, measure and translate RWE into meaningful and credible clinical insights.
So, what does this look like in practice?
In our clinics, still Emerald Clinics, we remain committed to providing access to medicinal cannabis and other
unregistered treatments for patients who have failed standard of care. Our team has done an exceptional
job adapting to COVID-19 – more appointments are being conducted online, patients’ health status tracked
remotely, and we are collecting meaningful data at multiple touchpoints with our service. I’m pleased to say
that demand for our clinical services, and collaboration with strategic partners, has never been greater and we
are developing valuable insights from the data that will inform future therapies.
Our Openly screening service, in development, is a considered investment in our long-term vision to bring a
new model of healthcare to people in their homes and in the community. This technology has the potential to
help people get back to work, study and leisure activities, safely. It is designed to measure vital signs, heart
rate and blood oxygen levels, in less than a minute, using just a smartphone. Our clinical team will be on
standby to monitor and learn from this information, ready to guide our clients on how to manage the health
and well-being of their people.
These are examples of what can be accomplished by combining an innovative clinical team with great
technology in response to changing health needs.
In the 2020/21 fiscal year, Emyria will be working to find our first corporate customers for Openly as we move
forward with refining and testing the technology.
We will be investigating options for expanding Emerald Clinics generally, including establishing a clinical
service in the UK as part of our contract with Spectrum Biomedical UK, in addition to our four clinics in Australia.
We also intend to partner with more groups and organisations interested in our increasingly valuable
real-world data as we work to develop multiple, growing revenue streams and invest in developing our own
intellectual property from our data assets.
COVID-19 has changed a number of industries, especially healthcare. Digital health tools, remote patient
monitoring and RWE are firmly the future of medicine – a future Emyria is uniquely positioned to lead.
Thanks to our shareholders, partners, fellow Board members, management team and clinical teams for your
support during the financial year. You are valued partners in our innovation and our success.
Dr Stewart Washer
4
EMYRIA CHAIRMAN
Thank you. Our shareholders, business
associates and supporters are valued partners
in Emyria’s continued innovation and success.
Dr Stewart Washer
EMYRIA EXECUTIVE CHAIRMAN
A world-class team
Our Board
Medical Key Opinion Leaders
Dr Stewart Washer
Dr Jennifer Morgan
EXECUTIVE CHAIRMAN
MEDICAL ADVISOR
Dr Michael Winlo
Dr Philip Finch
MANAGING DIRECTOR
MEDICAL ADVISOR
Prof Alistair Vickery
Dr Nik Zeps
MEDICAL DIRECTOR
MEDICAL ADVISOR
Mr Matthew Callahan
Prof David Putrino
NON-EXECUTIVE DIRECTOR
MEDICAL ADVISOR
Prof Sir John Tooke
NON-EXECUTIVE DIRECTOR + MEDICAL ADVISOR
Visit our website emyria.com to view the full credentials of our Board, Medical Advisory Board
and Management Team.
6
We’re on a great mission. We’ve deliberately put ourselves at
the front line of care delivery, as well as evidence generation
for patients with high unmet needs, which means our unique
insights can improve the care we provide and the speed of
development for the novel treatments we work with.
Dr Michael Winlo
EMYRIA MANAGING DIRECTOR
Welcome to Emyria
Caring. Curious. Courageous.
Emyria’s primary goal is to improve the efficacy of novel treatments and therapies – and to provide more
effective and personalised healthcare.
We do this by developing technology-powered health services and data products, which are designed to help
us learn from every patient in order to deliver deeper clinical insights.
People are at the centre of everything we do.
We listen with great care to each and every person we set out to help, and leverage the power of technology to
accurately capture their clinical outcomes and experiences. We use novel interventions and new technologies
to elevate and personalise their standard of care.
Our business model, underpinned by sophisticated data systems, allows us to simultaneously capture valuable
clinical insights – quality evidence that helps to empower clinicians, regulators and our partners to service
unmet healthcare needs in a variety of clinical and real-world settings.
Emyria’s intuitive model of healthcare performs, well beyond the clinic.
Our team has invested energy in a number of important programs this year and has formed three primary
clinical services for Emyria.
Maritime
Health
Clinic
Testing and validating
unregistered medicines
including cannabinoids
using live, real-world
patient data.
There is an immense volume
of anecdotal support for
cannabinoid-based medicines
(CBMs), but a dearth of
high-quality, product-specific
clinical evidence. Our purposebuilt clinics, Emerald Clinics,
and leading clinicians provide
access to novel CBMs, with the
support of technology designed
to capture real-world clinical
evidence in partnership with
every single patient. We are
developing opportunities with
partners wanting to test other
unregistered therapeutics,
leveraging the unique capabilities
of our clinics and data team.
8
Health screening, powered
by a smartphone and
backed by a clinical team.
Improving treatments
for chronic pain with
multidimensional RWE.
Under devopment, our clinicianled remote health screening
and monitoring app, Openly,
is designed to measure heart
rate and blood oxygen levels
in less than a minute, using just
the camera on a smartphone.
Openly has potential to be
used to support proactive
health screening in response
to COVID-19, so people can
safely gather together for work,
study and play – and is a fine
example of Emyria’s long-term
commitment to delivering care,
well beyond the clinic.
GP clinic Maritime Health has
been using Emryia’s research
platform to manage, monitor
and improve the safety and
efficacy of novel treatments for
chronic pain. The practice is also
using our platform to generate
dynamic patient data to
improve treatments for a range
of other debilitating and costly
health issues, including mental
health, sleep, addiction and
musculoskeletal conditions and
problems. We currently have two
clinics in NSW.
We deliver great care and insights
Hea
Patient care emphasis
High quality care and data
Data quality emphasis
Real World Evidence, at a glance
47% of FDA approvals
currently leverage RWE
RWE market worth
USD $1.64 billion by 20241
From the US Food and Drug Administration (FDA)2
data (RWD) are the data relating to patient health status and/
or the delivery of health care routinely collected from a variety of sources.
RWD can come from a number of sources, for example: electronic health
records (EHRs); claims and billing activities; product and disease registries;
patient-generated data including in home-use settings; and data gathered
from other sources that can inform on health status, such as mobile devices.
Real-world evidence (RWE) is the clinical evidence regarding the usage and
potential benefits or risks of a medical product derived from analysis of RWD.
RWE can be generated by different study designs or analyses, including but
not limited to, randomised trials, including large simple trials, pragmatic
trials, and observational studies (prospective and/or retrospective).2
1
Source: Meticulous Market Research (meticulousresearch.com) 2 Source: FDA.gov
9
Review of operations
Emerald Clinics, now Emyria Limited, listed on the Australian Securities Exchange (ASX) on 12 February 2020
after raising AU$6 million in an initial public offering, as a company consisting of patient-focused medical
clinics across Australia gathering real-world evidence (RWE) on the efficacy of cannabinoid medicines.
Just weeks later, the COVID-19 crisis escalated across the globe and changed dynamics in the healthcare
sector significantly.
Emyria accelerated the development and expansion of its telehealth services rather than in-person visits.
In addition to engaging with patients over the phone or via video conference, the Emyria platform allowed
clinicians to integrate patient monitoring tools and medical records.
The Company’s telehealth service also allowed it to gather valuable RWE on the efficacy of cannabinoid-based
medicine on patients remotely.
As the pandemic worsened, Emyria was appointed as Program Manager to develop a national clinical data
and analytics platform of COVID-19 patient cases in a partnership between NSW Health, Queensland Health,
QUT, the University of Sydney, Monash University and the Federal Government.
The Company also worked to enrol patients in a Phase 1 dose escalation trial for Zelira Therapeutics, serving as
a second site for tests of its medicinal cannabinoid oil formulation in patients with non-cancer pain.
In June, Emyria developed the Openly service to provide remote vital signs monitoring using just the camera
on a smart phone. While the technology is still in development, if successful, it will allow Emyria’s platform to
capture and measure vital signs such as heart rate and blood oxygen levels using just a smartphone camera.
Debut on the ASX – and beyond
FEBRUARY 2020
Emerald Clinics
listed on the
Australian Securities
Exchange (ASX),
ticker code EMD,
raising AU$6m.
Signed research
agreement to
accelerate
Zelira Therapeutics’
opioid sparing
clinical trial.
Professor
Sir John Tooke
was appointed to
the Board at listing.
Professor Sir Tooke is
a highly respected
thought leader in
learning health
systems and
clinical research.
Professor Sir Tooke
was knighted for his
services to medicine
in 2007.
10
MAY 2020
JUNE 2020
Emerald Clinics
appointed program
manager of
National Clinical
Data and Analytics
Platform (CDAP)
targeted at
COVID-19 response.
Emerald Clinics
announced a
collaboration
to bring their
AI-powered,
contactless vital
sign technology
into its RWE
platform. This
deep integration,
once validated,
will allow Emerald
to capture vital
signs, alongside
important symptom
data, using
just a patient’s
smartphone. This
project is now
branded as Openly.
The Company finished the financial year
with revenues of $1.5 million,
In early FY2021, Emyria signed a RWE contract with
Spectrum Biomedical UK to develop a RWE asset in the
United Kingdom. Spectrum is the UK subsidiary of the
world’s largest cannabis company, Canopy Growth, and
under the contract the Company will receive an upfront
fee of £150,000, with the capability to earn as much as
£400,000 (~A$723,000).
a 987% increase from the previous
year, and $3.7 million in cash and cash
equivalents. A $2.2 million institutional
placement in August 2020 further
strengthened Emyria’s capital position.
Under the contract, the company will maintain independence in how it delivers the clinical care to patients,
allowing the ability to establish a UK-based clinic or partner with existing services.
Since the end of the financial year Emyria announced it had achieved record appointments for its clinical
services in Australia, despite the majority of health services trending downwards due to COVID-19. As a result,
the Company is actively hiring clinicians to meet growing demand for its clinical services, expanding its remote
monitoring capabilities and increasing its data insight platforms.
The Company is also well positioned to benefit from an interim decision delivered by the Therapeutic Goods
Administration (TGA) on 9 September 2020, which is recommending that low dose cannabinoid products (CBD)
be made available in Australian pharmacies without a prescription as a Schedule 3 medicine.
Registration of “low dose CBD” products would require a full submission to the TGA and the type of high-quality
evidence to support safety and effectiveness that it is Emyria’s business to provide.
AUGUST 2020
Emerald Clinics
signs contract
with the UK-based
biopharmaceutical
arm of the largest
cannabis company,
Canopy Growth UK,
to develop RWE
system in the UK.
Emerald Clinics
successfully raise
AU$2.2m
in placement.
SEPTEMBER 2020
The Openly app is
registered with the
Therapeutic Goods
Administration
(TGA) as a Class 1
medical device.
Emerald signs
professional services
agreement with
Mt Sinai Hospital’s
Precision Recovery
Team.
Emerald Clinics
finalises name
change to
Emyria Ltd
(ASX:EMD)
and breaks out
Emerald Clinics as
patient-services
arm of the business.
11
Emerald Clinics
Novel treatments, quality data
Emerald Clinics is focused on the development of
high-quality real-world evidence (RWE) around
the safe and effective use of unregistered
medicines such as pharmaceutical-grade
cannabinoid-based medicines (CBMs).
While the medicinal cannabis sector has gained
significant momentum globally, an almost
complete lack of high-quality, product specific
clinical data has constrained the uptake of
CBMs by clinicians, restrained approval by
regulators and prevented reimbursement by
insurance companies.
Emyria has opened patient-focused medical
clinics in NSW, VIC and WA to provide safe access
12
to novel treatments for suitably qualified patients,
in collaboration with referring doctors. These
clinics will remain trading as Emerald Clinics in
market and continue to serve a diverse patient
population, highly motivated to access novel
treatments and evidence-based care.
“Since opening our first clinic in December 2018,
Emerald Clinics has grown its patient base to
over 1000 within the first 12 months. Our data
model is now providing new insights into how
best to prescribe and use CBMs and is already
demonstrating patient benefits by enabling
reduced use of opioids and improved health
outcomes,” said Emyria MD, Dr Michael Winlo.
Clinical leadership, in real world settings
The Emerald Clinics’ data-centric business model has gained attention in the age of COVID-19.
In March 2020, following leadership in the conversation and technological shift to telehealth
internationally, Emerald Clinics was appointed program manager for the development of a national
Clinical Data and Analytics Platform (CDAP) of COVID-19 patient cases.
CDAP aims to capture clinical and real-world data to provide real-time clinical decision support for
COVID-19 patients. This is supported by Emerald’s real-world evidence platform, clinician-monitored
alert systems and telehealth service.
The platform was established by the Digital Health Cooperative Research Centre, a partnership between
NSW Health, Queensland Health, QUT, the University of Sydney, and Monash University.
“We are very pleased to have been chosen to help coordinate the development of this platform as it
is a recognition of Emerald’s unique expertise in real-world evidence and building learning health
systems,” said Emryia MD, Dr Michael Winlo.
The reach and impact of Emerald’s data platform will continue to grow, with multiple clinical trial and
collaboration opportunities now secured in addition to this CDAP opportunity.
Addressing challenges in RWE
Regulators are increasingly accepting of real-world evidence (RWE), realising it can fill crucial knowledge
gaps for clinicians, regulators and drug developers eager to learn whether treatments are safe and effective
in diverse patient populations. We founded Emyria to address major RWE challenges – as shown in the figure
below. Our Company is committed to the highest standards of RWE, at every stage of the process, as we
collect, curate and contextualise valuable clinical insights, in partnership with our patients.
Challenges in RWE
Access to quality data
35%
Applying data correctly to evidence strategy
30%
Selecting the right data sets
25%
Data integration and management
20%
Proper analysis of data
20%
Validating RWE generated
10%
SHYFT Analytics recently commissioned in-depth interviews with RWE decision-makers across biopharma
companies. This graph represents the percentage of respondents who identified challenges in different
areas of RWE.
13
Openly
Connect your people
Healthcare models have been pushed to new,
often devastating, limits during the COVID-19
crisis. What the pandemic has shown, at speed, is
the importance of real-world evidence (RWE) and
Emyria’s commitment to providing patient-centric
healthcare at home and in the community.
Emyria is in the process of developing a new app
called Openly, which aims to make meeting and
working on the frontline, safer.
The technology harnesses video and artificial
intelligence (AI) to support the capture of
vital signs in a completely contactless manner
by measuring subtle changes in colour
(micro-blushes) of the skin, pixel by pixel, in less
than a minute. Combining this technology with
data monitoring and telehealth consultations,
will create the potential for people to be actively
screened prior to meeting up in groups.
“Vital signs, such as heart rate and blood oxygen
levels, provide clinically relevant data, but are
often difficult to obtain from patients remotely.
Openly collects this information using a smart
phone camera and it is then processed and
analysed, remotely, with the help of our RWE
platform and clinical team,” said Emyria MD,
Dr Michael Winlo.
“Openly was registered by the TGA in September
2020. Its fast tracked success is a prime example
of what can happen when you bring together
an agile clinical service, which understands
patient needs and risks, with world-class
technology partners. We are immensely proud
of this innovation.”
Openly is being designed to help people get
back to work and communities to reconnect.
14
Openly featured
on The Today Show
The Openly app is being developed at a time
when industries of all shapes and sizes are
deeply committed to monitoring the health
of communities.
Channel 9’s Today Show broadcast a three-minute
feature story on the technology in late August,
showing an example of how it could work in
practice and a demonstration onsite at the Emyria
headquarters in Perth, WA.
“The team of GPs is what sets this system apart,”
said Today Show reporter, Michael Genovese in his
story to preview the potential capabilities of
this technology.
Openly workflow
App
Control Centre
1.
2.
3.
Risks & Symptoms
Vital Signs
Alerts
Participants prompted by
SMS, email or notification
to complete a “One Minute
Daily Review” of risk
factors and symptoms
Vital sign information
collected to improve
objective clinical
assessment
Evidence-based risk
scoring applied based on
patient inputs
Wellness Triage
HIGH
MEDIUM
LOW
Status
Control Centre
Optional: Based on
results, a ‘status’ and other
educational information
can be delivered to
participants
4.
5.
Clinical Screening
Management
Clinical team monitors
alerts and responds
with direct tele-health
consultation or coordinates
referral to appropriate
service
LOW
MEDIUM
< 24 hours
HIGH
DATA
= Continue daily
review
Immediate
Telehealth
Testing?
COVID-19+ve
COVID-19-ve
Referral into supportive
monitoring program
Continue with
15
Directors’ Report
The directors present their report for Emerald Clinics Limited (“Emerald” or “the Company”) and its subsidiaries
(“the Group”) for the financial year ended 30 June 2020.
Directors
The names of the directors in office at any time during or since the end of the year ended are:
Dr Stewart Washer
Executive Chairman
Dr Michael Winlo
Managing Director
(appointed on 26 November 2019 and was previously Chief Executive Officer)
Professor Alistair Vickery
Executive Medical Director
Dr Patrizia Derna Washer
Research Director
(resigned on 28 October 2019)
Mr Matthew Callahan
Non-Executive Director
Professor Sir John Tooke
Non-Executive Director
(appointed on 10 February 2020)
Review of operations
During the financial year ended 30 June 2020, the Company became listed on the Australian Securities
Exchange on 12 February 2020 and its initial public offering raised $6 million (before costs). The Group
continued to provide a high level of care for its patients through Emerald’s specialist clinics whilst gathering
Real-World-Evidence (“RWE”) insights for unregistered treatments such as cannabinoid-based medicines. To
enhance the Group’s digital health platform, Emerald has invested in monitoring technology to enable remote
data capture from its patients.
Significant changes in state of affairs
On 10 July 2019, the Company issued 3,500,000 options to Dr Michael Winlo for an exercise price of $0.45 per
share and expiring on 13 June 2023. The vesting conditions are:
•
One third immediately on issue;
•
One third one year from date of issue subject to continued employment or service and;
•
One third two years from date of issue subject to continued employment or service.
On 18 July 2019, the Company entered into a strategic collaborative agreement with Zelira Therapeutics
Limited where licence fees were payable in exchange for the provision of dose dependent efficacy insights.
On 7 August 2019, the Company incorporated four wholly owned subsidiaries namely:
16
•
Emerald Clinical Network Pty Ltd
•
Emerald Clinical Research Pty Ltd
•
Emerald Data Management Pty Ltd
•
Emerald IP Holdings Pty Ltd
Directors’ Report
On 26 September 2019, the Company entered into a heads of agreement with Australian Medical Research
and as part of the agreement was issued 600,000 options for an exercise price of $0.45 per share and expiring
on 13 June 2023. The vesting conditions are:
•
200,000 options vested immediately on date of issue;
•
200,000 options vest after 12 months after date of issue and;
•
200,000 options vest after 18 months after date of issue.
On 30 September 2019, the Company entered into a strategic collaborative agreement with
Canopy Growth Australia Pty Ltd where licence fees are payable in exchange for the provision of
product specific insights.
On 30 September 2019, the Company appointed Su-Mei Sain as Chief Financial Officer of the Company.
On 24 October 2019, the Company issued 1,000,000 options to Dr Phil Finch for an exercise price of
$0.45 per share and expiring on 13 June 2023. The vesting conditions are:
•
One third immediately on issue;
•
One third one year from date of issue subject to continued employment or service and;
•
One third two years from date of issue subject to continued employment or service.
On 11 November 2019, the Company issued 1,000,000 options to Mrs Su-Mei Sain for an exercise price of
$0.45 per share and expiring on 13 June 2023. The vesting conditions are:
•
One third immediately on issue;
•
One third one year from date of issue subject to continued employment or service and;
•
One third two years from date of issue subject to continued employment or service.
On 5 December 2019, the Company issued 2,777,778 fully paid ordinary shares at $0.18 per share raising
$500,000 of funds.
On 12 February 2020, the Company became listed on the Australian Securities Exchange (“ASX”) issuing
30 million ordinary shares at $0.20 per share giving the Company market capitalisation of $36.8 million. On
the date of the Company’s listing, the Convertible Note Subscription Deed expired and all notes outstanding
were converted to ordinary shares and have been issued. The Convertible Note value of $3,300,000 was
converted to 20,625,000 ordinary shares at $0.16 per share.
On 12 February 2020, Professor Sir John Tooke was appointed as Non-Executive Director of the Company.
On 27 February 2020, the Company commenced a sponsored Opioid Sparing Clinical Trial with
Zelira Therapeutics Limited.
On 1 April 2020, the Company entered into an agreement with University of Sydney to provide project advisory
services for the Clinical Data Analytics Platform targeted at COVID-19 patients.
On 30 April 2020, the Company entered into a Radium Capital loan agreement of $240,000 as a partial
advance against its accrued R&D tax rebate for the financial year ended 30 June 2020.
On 14 May 2020, the Company incorporated Openly Care Inc. in the United States of America
17
Directors’ Report
Events after reporting date
The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has been financially neutral for the
Group up to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the
reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian
Government and other countries, such as maintaining social distancing requirements, quarantine, travel
restrictions and any economic stimulus that may be provided.
On 10 August 2020, the Group announced on the ASX that it would be entering into a Real-World Evidence
contract with Spectrum Biomedical UK (“SBUK”) which is a subsidiary of Canopy Growth Corp (a Toronto
Exchange Security listed company TSX:TSE). Emerald will be responsible for collection of specific data points
including de-identified patient information, use of concomitant medicines, prescribed usage and diagnoses,
and a rate of patient reported outcome measures. This data will then be provided to SBUK as a per patient
pricing model. The contract value is up to GBP 400,000 (~AUD 723,000 and the Group is expected to receive
GBP 150,000 (~AUD 270,000) up front plus GBP 300 (~AUD 542) per patient. The contract term is 24 months.
On 14 August 2020, The Group announced on the ASX that it would be proposing a name change from
“Emerald Clinics Limited” to “Emyria Limited”. The name change is subject to approval by shareholder on
18 September 2020 and a notice of meeting was issued on 14 August 2020 on the ASX.
Apart from the above, there are no other matters or circumstances that have arisen since the end of the
financial year which have significantly affected or may significantly affect the operations of the Group, the
results of those operations, or the state of affairs of the Group in future financial periods.
Future development, prospects and business strategy
The Group will focus on developing its business which combines the treatment of patients and the capture of
high-quality clinical data to transform the way novel therapies are understood and researched. The Group will
then combine this data with health records and published information to generate powerful data sets that
provide actionable insights for physicians, drug developers, research groups and government departments.
The data asset developed, and associated technologies, will form the primary source of income for the Group,
generating license usage fees and royalties from third parties via a data-insights-as-a-service offerings while
also developing more effective clinical models internally.
Dividend paid and recommended
No dividends have been declared, provided for or paid in respect of the financial year ended 30 June 2020
(30 June 2019: nil).
18
Directors’ Report
Information On Directors And Company Secretary
Dr Stewart Washer – Executive Chairman (Appointed on 1 July 2018)
Stewart has 25 years of CEO and Board experience in medical and agrifood biotech companies. He is currently
the Executive Chairman of Emerald Clinics Ltd, Chairman of Orthocell Ltd (ASX:OCC), a regenerative medicine
company and Director of Cynata Therapeutics Ltd (ASX:CYP) stem cell therapies.
Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd that was
sold in 2015 for A$279m and was a Director of iCeutica that was sold to a US Pharma. He was also a Senator
with Murdoch University and was a Director of AusBiotech Ltd. Stewart was previously Chairman of Minomic
International Ltd cancer diagnosis and treatment and previously Director of Zelira Therapeutics Ltd (ASX:ZLD)
medical cannabis clinical studies and research.
Other current directorships of a public listed company
Cynata Therapeutics Limited – appointed as Director on 1 August 2013
Orth
Share your feedback
Discover